This article is for informational purposes only and does not constitute medical advice. Clinical trial eligibility and availability vary. Always consult a qualified healthcare professional before making any medical decisions or considering participation in a clinical trial.
Summary
Children are not small adults — their metabolism, physiology, and responses to drugs differ from adults in ways that matter enormously for drug safety and efficacy. Clinical trials involving children are more tightly regulated, slower to enroll, and more ethically complex than adult trials. Yet pediatric research is essential: many diseases manifest uniquely in childhood, and pediatric cancers, rare genetic diseases, and RSV prevention are areas where trials in 2026 are producing breakthroughs. This guide explains how pediatric trials work, what protections exist, and how families can navigate the decision to enroll a child.
Special Protections for Children in Clinical Trials
Federal regulations provide layered protections specific to pediatric research. The FDA's 21 CFR Part 50, Subpart D and the Common Rule (45 CFR Part 46, Subpart D) establish that clinical research involving children can only proceed when it meets one of four specific risk-benefit conditions, including situations where research offers direct benefit to the child, or where minimal risk or a minor increase over minimal risk accompanies potential direct benefit or important knowledge gain.
Key protections include: Parental permission — one or both parents must provide written consent. Child assent — children capable of understanding (typically 7+ years, case-by-case) must be asked for their agreement to participate; their refusal is respected in most circumstances. Independent safety monitoring — an independent Data Safety Monitoring Board (DSMB) reviews safety data regularly. IRB oversight — the Institutional Review Board must specifically evaluate pediatric research and, for certain high-risk studies, must involve a panel of non-institutional child welfare experts.
The Pediatric Research Equity Act (PREA) requires pharmaceutical sponsors to study new drugs in pediatric patients when those drugs are likely to be used in children. The Best Pharmaceuticals for Children Act (BPCA) provides market exclusivity incentives for voluntary pediatric studies. These laws have significantly increased the proportion of drugs that have been tested in children before or after approval.
Active Areas: Pediatric Rare Disease Trials
Children with rare genetic diseases represent the largest sector of pediatric clinical trials. With over 7,000 known rare diseases and ~80% having a genetic basis, many conditions manifest primarily in childhood — spinal muscular atrophy (SMA), Duchenne muscular dystrophy, Gaucher disease, Pompe disease, and hundreds of ultra-rare conditions affecting dozens to hundreds of children.
SMA exemplifies the transformation possible: gene therapy with onasemnogene abeparvovec (Zolgensma) when given before symptoms appear (pre-symptomatic newborn screening identified) now results in essentially normal motor development in most children — a condition that previously caused death by age 2. Duchenne muscular dystrophy trials are evaluating multiple exon-skipping ASOs and gene therapy approaches including micro-dystrophin delivery.
The FDA's Rare Pediatric Disease designation and Priority Review Vouchers (worth ~$100–150 million when sold) provide powerful incentives for companies to pursue ultra-rare pediatric diseases. Natural history studies — tracking disease progression without treatment — are critical for rare diseases to establish what outcomes to measure in trials.
RSV Prevention: A Pediatric Triumph
Respiratory syncytial virus (RSV) is the leading cause of infant hospitalization in the US, responsible for approximately 58,000–80,000 hospitalizations annually in children under 5. For decades, prevention was limited to monthly palivizumab injections for the highest-risk premature infants — a costly and burdensome regimen.
2023 brought two paradigm-changing approvals: Nirsevimab (Beyfortus) is a long-acting monoclonal antibody given as a single injection to newborns and infants that protects for the entire RSV season. The MELODY trial showed 74.5% reduction in RSV lower respiratory tract infection requiring medical attention. Maternal RSV vaccination (Abrysvo, Pfizer) given during pregnancy transfers antibodies to the fetus, protecting newborns from birth. The MATISSE trial showed 81.8% efficacy against severe RSV disease in infants 0–90 days old.
Current trials in 2026 are evaluating nirsevimab for RSV season after the first year of life (SYMPHONY trial), and next-generation mRNA RSV vaccines for young children are in Phase 2.
Childhood Cancer Research
The Children's Oncology Group (COG) operates one of the largest pediatric clinical trial networks in the world, with over 200 member institutions. Pediatric cancers — leukemia, brain tumors, lymphomas, and sarcomas — differ biologically from adult cancers and require dedicated research. The 5-year survival for childhood ALL has risen from ~10% in 1960 to over 90% today through successive cooperative group trials.
Current priority areas include: immunotherapy for pediatric solid tumors (which historically respond poorly to checkpoint inhibitors); CAR-T expansion for relapsed/refractory ALL; targeted therapy for pediatric brain tumors based on molecular profiling (BRAF V600E mutations in pediatric glioma are now targetable with dabrafenib/trametinib); and reducing long-term treatment toxicity in cancers where cure rates are already high. The ZAP70 inhibitor zanubrutinib and daratumumab are in pediatric trials.
How Parents Navigate Pediatric Trial Enrollment
The decision to enroll a child in a clinical trial is emotionally complex. For serious or rare conditions without approved treatments, trials may offer the only access to an experimental therapy. Key steps for families include consulting the child's specialist at an academic medical center with research programs; searching ClinicalTrials.gov with the disease name and "pediatric" or age range filter; contacting disease-specific advocacy organizations (who often maintain trial registries and have patient navigators); and requesting a second opinion at a major academic or specialized children's hospital if a trial is geographically distant.
Key Takeaways
- Pediatric trials require both parental consent and child assent; children's refusal to participate is respected under federal research regulations.
- The Pediatric Research Equity Act and Best Pharmaceuticals for Children Act have significantly increased pediatric drug testing requirements and incentives.
- Nirsevimab (Beyfortus) and maternal RSV vaccination have transformed RSV prevention for infants — together covering virtually all newborns at risk.
- Gene therapy has made SMA a potentially preventable disease when identified by newborn screening; similar precision approaches are in trials for DMD and other genetic conditions.
- The Children's Oncology Group and disease-specific advocacy organizations are the best starting points for families seeking pediatric trial information.